RICERCA
AUTORI
RIVISTE
Sfoglia per RIVISTA
JOURNAL OF CLINICAL ONCOLOGY
Collezione AOU San Luigi di Orbassano
Items : 57
Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21) in Journal of Clinical Oncology
2021
AOU San Luigi di Orbassano
Procopio G; Mennitto A; Di Maio M; Zattarin E; Maruzzo M; De Giorgi U; Santini D; Buti S; Casadei C; Soraru M; Di Lorenzo G; Messina C; Mucciarini C; Roviello G; Buttigliero C; Stellato M; Sepe P; Pignata S; De Braud FG; Verzoni E;
TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) in Journal of Clinical Oncology
2021
AOU San Luigi di Orbassano
De Bono JS; Mehra N; Higano CS; Saad F; Buttigliero C; Van Oort IM; Mata M; Chen H-C; Healy CG; Czibere A; Fizazi K;
Gray areas and evidence gaps in the management of rectal cancer as revealed by the comparison of recommendations from national and international clinical guidelines in Journal of Clinical Oncology
2020
AOU San Luigi di Orbassano
Bregni G; Telli TA; Camera S; Baratelli C; Shaza L; Deleporte A; Moretti L; Liberale G; Hendlisz A; Sclafani F;
Surgery for stage IV gastric cancer: An Italian perspective in Journal of Clinical Oncology
2020
AOU San Luigi di Orbassano
Bencivenga M; Ministrini S; Solaini L; Marino E; d'Ignazio A; Mura G; Sofia S; Cipollari C; Marrelli D; Degiuli M; Donini A; Roviello F; Morgagni P; De Manzoni G; Tiberio G;
TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)-First interim analysis (IA) in Journal of Clinical Oncology
2020
AOU San Luigi di Orbassano
De Bono JS; Mehra N; Higano CS; Saad F; Buttigliero C; Mata M; Chen H-C; Healy CG; Paccagnella ML; Czibere A; Fizazi K;
Atezolizumab (atezo) therapy for upper tract (UT) urothelial carcinoma (UC): Subgroup analysis of the single-arm international SAUL study in pretreated locally advanced/metastatic urinary tract carcinoma in Journal of Clinical Oncology
2020
AOU San Luigi di Orbassano
Sternberg CN; Loriot Y; Tambaro R; Buttigliero C; Morelli F; Papai Z; Retz M; Necchi A; Van Der Heijden MS; Faust G; Zorrilla AFC; Lainez N; Panni S; Etxaniz O; Krieger L; José Mendez Vidal MJ; Los M; De Ducla S; Fear S; Merseburger AS;
Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study in Journal of Clinical Oncology
2020
AOU San Luigi di Orbassano
Iacovelli R; Buti S; Buttigliero C; De Vivo R; Caserta C; Ferraú F; Galli L; Martelli V; Masini C; Mattioli R; Merler S; Milesi L; Naglieri E; Ricotta R; Rizzo M; Sacco C; Santini D; Tambaro R; Verri E; Santoni M;
Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study) in Journal of Clinical Oncology
2020
ASL Cuneo 2
AOU San Luigi di Orbassano
Vitale MG; Zucali PA; Milella M; Santoni M; Procopio G; Ortega C; Naglieri E; Massari F; Fornarini G; Di Lorenzo G; Chiuri VE; Calabro F; Fantinel E; Buttigliero C; Bracarda S; Bonomi L; Bersanelli M; Basso U; Atzori F; Iacovelli R;
Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study in Journal of Clinical Oncology
2020
AOU San Luigi di Orbassano
Masini C; Iotti C; De Giorgi U; Bellia RS; Buti S; Salaroli F; Zampiva I; Mazzarotto R; Mucciarini C; Baldessari C; Bruni A; Procopio G; Kinspergher S; Nole F; Morelli F; Baier S; Buttigliero C; Berselli A; Pinto C;
TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) -updated interim analysis (IA) in Journal of Clinical Oncology
2020
AOU San Luigi di Orbassano
De Bono JS; Mehra N; Higano CS; Saad F; Buttigliero C; Van Oort IM; Mata M; Chen H-C; Healy CG; Paccagnella ML; Czibere A; Fizazi K;
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223) in Journal of Clinical Oncology
2020
ASL Asti
AOU San Luigi di Orbassano
Caffo O; Frantellizzi V; Tucci M; Galli L; Monari F; Baldari S; Masini C; Bortolus R; Facchini G; Alongi P; Zichi C; Biasco E; Fanti S; Pignata S; Filice A; Borsatti E; Rossetti S; Spada M; Cortesi E; De Vincentis G;
Seuencing chemotherapy and immune checkpoint inhibitors C in metastatic urothelial carcinoma UC: Meet-Uro1 study in Journal of Clinical Oncology
2019
AOU San Luigi di Orbassano
Bandini M; Farè E; Raggi D; De Giorgi U; Banna GL; Basso U; Losanno T; Bersanelli M; Buti S; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Ficorella C; Caffo O; Naglieri E; Pederzoli F; Pignata S; Necchi A;
Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial in Journal of Clinical Oncology
2019
AOU San Luigi di Orbassano
Morano F; Niger M; Corallo S; Lonardi S; Tamberi S; Di Donato S; Giommoni E; Giuliani F; Frassineti GL; Tomasello G; De Vita F; Cardellino GG; Pinotti G; Brizzi MP; Rimassa L; Scartozzi M; Berardi R; De Braud FG; Pietrantonio F; Di Bartolomeo M;
Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016 in Journal of Clinical Oncology
2019
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; ButtIgliero C; Tucci M; Aglietta M; Scagliotti GV; Perrone F; Di Maio M;
Biases in assessment and reporting of health-related quality of life (QoL): A systematic review of oncology randomized phase III trials published between 2012 and 2016 in Journal of Clinical Oncology
2018
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; Marcato M; Bironzo P; Aglietta M; Scagliotti GV; Perrone F; Di Maio M;
Survival outcomes from a cumulative analysis from worldwide observational studies on sequential use of new agents (NAs) in metastatic castration-resistant prostate cancer (mCRPC) (CASTOR study) in Journal of Clinical Oncology
2018
AOU San Luigi di Orbassano
Caffo O; Wissing M; Bianchini D; Bergman AM; Thomsen FB; Schmid S; Yu EY; Bournakis E; Sella A; Basso U; De Giorgi U; Tucci M; Gelderblom H; Galli L; Sperduti I; Oudard S;
Sequencing radium 223 (RA223) for metastatic castration-resistant prostate cancer (mCRPC) patients (PTS) in the daily practice: Preliminary results from a retrospective study in Italian centers in Journal of Clinical Oncology
2018
AOU San Luigi di Orbassano
Caffo O; Frantellizzi V; Monari LGF; Facchini G; Baldari S; Tucci M; Bortolus FAR; Agostini S; Biasco E; Fanti S; Rossetti S; Pignata S; Zichi C; Salgarello M; Borsatti E; Sbrana ECA; Vincentis GD;
Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study in Journal of Clinical Oncology
2017
AOU San Luigi di Orbassano
Caffo O; Bria E; De Giorgi U; Tucci M; Galli L; Fratino L; Rossetti S; Iacovelli R; Re GL; Mosillo C; Gasparro D; Guglielmini PF; Damiani A; Procopio G; De Lisi D; Ruatta F; Scagliarini S; Donini M; Sperduti I; Basso U;
Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study in Journal of Clinical Oncology
2017
AOU San Luigi di Orbassano
Cremolini C; Morano F; Moretto R; Berenato R; Tamborini E; Perrone F; Rossini D; Gloghini A; Busico A; Zucchelli G; Baratelli C; Tamburini E; Capone I; Volpi C; Milione M; Di Maio M; Fontanini G; De Braud FG; Falcone A; Pietrantonio F;
Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castrationresistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Final results from a multicenter Italian study in Journal of Clinical Oncology
2017
AOU San Luigi di Orbassano
Caffo O; Bria E; De Giorgi U; Tucci M; Biasco E; Fratino L; Facchini G; Iacovelli R; Re GL; Scagnoli S; Morelli F; D'Angelo A; Verderame F; Campadelli E; Ricotta R; Napolitano M; Sartori D; Borsellino N; Sperduti I; Maruzzo M;
Patients with metastatic castration-resistant prostate cancer (mCRPC) are primary resistant (PR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA in Journal of Clinical Oncology
2017
AOU San Luigi di Orbassano
Caffo O; Bria E; De Giorgi U; Tucci M; Biasco E; Fratino L; Rossetti S; Iacovelli R; Morelli F; D'Angelo A; Campadelli E; Verderame F; Borsellino N; Sartori D; Guida A; Ricotta R; Barni S; Maines F; Sperduti I; Zagonel V;
Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in pts with metastatic castration-resistant prostate cancer (mCRPC) receiving a new agent (NA)-based third-line treatment: Final results from a multicenter Italian study in Journal of Clinical Oncology
2017
AOU San Luigi di Orbassano
Caffo O; Bria E; De Giorgi U; Tucci M; Galli L; Fratino L; Rossetti S; Iacovelli R; Re GL; Mosillo C; Gasparro D; Guglielmini P; Damiani A; Procopio G; De Lisi D; Ortega C; Scagliarini S; Donini M; Sperduti I; Basso U;
Randomized, double-blind, placebo-controlled trial of evofosfamide (Evo) and pemetrexed (Pem) in advanced non-squamous non-small cell lung cancer (n-s NSCLC) in Journal of Clinical Oncology
2016
AOU San Luigi di Orbassano
Csõszi T; Goldman JW; Szilasi M; Von Pawel J; Novello S; Carter CA; Ciuleanu T-E; Del Conte A; Chatta G; Schenker M; Robert F; Orlov S; Zajda K; De Marinis F; Bennett CL; Kroll S; Pearce TE; Belani C;
Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP) in Journal of Clinical Oncology
2016
AOU San Luigi di Orbassano
Saad F; Keizman D; O'Sullivan JM; Carles J; Wirth M; Gillessen S; Thellenberg-Karlsson C; Miller K; Tucci M; Paganelli G; Procopio G; Gratt J; Seger M; Nilsson S; Heinrich D;
NiCord single unit expanded umbilical cord blood transplantation: Results of phase I/II trials in Journal of Clinical Oncology
2016
AOU San Luigi di Orbassano
Horwitz M; Montesinos P; Kurtzberg J; Valcarcel D; Jagasia MH; Cilloni D; Boelens JJ; Sanz GF;
PRO-BMI study: Prognostic role of body mass index (BMI) in metastatic castration resistant prostate cancer (mCRPC) patients receiving chemotherapy in Journal of Clinical Oncology
2016
AOU San Luigi di Orbassano
Tucci M; Lutrino SE; Di Maio M; Procopio G; Massari F; Calvani N; Fontanella C; Atzori F; Barni S; Caliolo C; Vignani F; Accettura C; Quaranta A; Mazzoni E; D'amico M; Scavelli C; Chetrì MC; Ferrara P; Cinieri S;
2016
AOU San Luigi di Orbassano
Yang JC-H; Popat S; Novello S; Groen HJM; Perol M; Felip E; Griesinger F; Reckamp KL; Lee J-S; Smit EF; Blakely CM; Akerley WL; Kim Y-C; Bazhenova L; Califano R; Delmar Hall R; Georgiou P; Isaacson JD; Golsorkhi T; Wakelee HA;
Effect of radium 223 on remission of bone metastases in androgen receptor-positive (AR+) salivary duct carcinoma (SDC) of the parotid in Journal of Clinical Oncology
2016
AOU San Luigi di Orbassano
Airoldi M; Pedani F; Bellini E; Contu V; Tucci M; Podio V; Raimondo L; Garzaro M;
A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140) in Journal of Clinical Oncology
2016
AOU San Luigi di Orbassano
Hassan R; Jennens R; Van Meerbeeck JP; Nemunaitis JJ; Blumenschein GR; Fennell DA; Kindler HL; Novello S; Elbi C; Walter A; Serpico D; Siegel JM; Childs BH;
A randomized, placebo-controlled study of amatuximab in combination with pemetrexed and cisplatin (P/C) as front-line therapy for subjects with malignant pleural mesothelioma (MPM) in Journal of Clinical Oncology
2016
AOU San Luigi di Orbassano
Hassan R; Fennell D; Scherpereel A; Nowak AK; Von Pawel J; Novello S; McLaughlin M; Hoffman K; Wallin BA;
Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes in Journal of Clinical Oncology
2016
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Maines F; De Giorgi U; Facchini G; Fratino L; Gasparro D; Alesini D; Basso U; Tucci M; Ortega C; Scagliarini S; Verderame F; Barni S; D'Angelo A; Vicario G; Donini M; Carrozza F; Sava T; Sirotova Z; Santini D; Caffo O;
Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Preliminary results from a multicenter Italian study in Journal of Clinical Oncology
2016
AOU San Luigi di Orbassano
Caffo O; De Giorgi U; Alesini D; Fratino L; Ortega C; Tucci M; Scagliarini S; Zagonel V; Zucali PA; Morelli F; Sartori D; Sabbatini R; D'Angelo A; Donini M; Barni S; Procopio G; Sirotova Z; Sava T; Conteduca V; Galligioni E;
2016
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Veccia A; De Giorgi U; Facchini G; Fratino L; Gasparro D; Alesini D; Basso U; Tucci M; Ortega C; Scagliarini S; Verderame F; Lo Re G; Procopio G; Sabbatini R; Campadelli E; Zucali PA; Morelli F; Sartori D; Conteduca V; Caffo O;
Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study in Journal of Clinical Oncology
2016
AOU San Luigi di Orbassano
Caffo O; De Giorgi U; Ferrau F; Donini M; Facchini G; Maruzzo M; Tucci M; Conteduca V; Maines F; Rossi L; Veccia A; Galligioni E;
Adjuvant therapy and outcomes in patients with stage IA breast cancer in Journal of Clinical Oncology
2015
AOU San Luigi di Orbassano
Arpino G; Giuliano M; De Angelis C; Di Maio M; Schettini F; Von Arx C; Riccardi F; Palumbo G; De Laurentiis M; Crispo A; Montella M; Grimaldi M; Trunfio M; Limite G; Accurso A; De Placido S;
Association between levels of hormones implied in steroid biosynthesis pathway and activity of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): An exploratory analysis in Journal of Clinical Oncology
2015
AOU San Luigi di Orbassano
Tucci M; Vignani F; Bertaglia V; Buttigliero C; Berruti A; Scagliotti GV; Di Maio M;
Validation of ERCC1 (E1) for response prediction to platinumgemcitabine in Journal of Clinical Oncology
2015
AOU San Luigi di Orbassano
Bepler G; Chen W; Patrick S; Astrow SH; Stephens C; Gandara DR; Rosell R; Ramirez JL; Scagliotti GV; Busso S; Volante M; Novello S;
Individual patients data analysis (IPD) of three randomized studies comparing erlotinib (E) with chemotherapy (CT) in patients with advanced wild-type epidermal growth factor receptor (wtEGFR) non-small cell lung cancer (NSCLC) in Journal of Clinical Oncology
2015
AOU San Luigi di Orbassano
Torri V; Ando M; Rulli E; Floriani IC; Kawaguchi T; Isa S-C; Gregorc V; Novello S; Barni S; Cinquini M; Marsoni S; Farina G; Garassino MC;
Patient self-evaluation of side-effects related to adjuvant chemotherapy in breast cancer: A prospective study in Journal of Clinical Oncology
2015
ASL Torino 4
ASL Asti
AOU San Luigi di Orbassano
ASL VCO
Montemurro F; Mittica G; Cagnazzo C; Foresto M; Longo V; Berchialla P; Solinas G; Culotta P; Martinello R; Calori A; Grasso B; Volpone C; Bertola G; Parola G; Del Torre M; Giuliano PL; Aglietta M; Ballari A;
Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study in Journal of Clinical Oncology
2015
AOU San Luigi di Orbassano
Caffo O; De Giorgi U; Facchini G; Fratino L; Gasparro D; Basso U; Alesini D; Tucci M; Ortega C; Verderame F; Procopio G; Lo Re G; Campadelli E; Omarini C; Donini M; Morelli F; Zucali PA; Sartori D; Conteduca V; Galligioni E;
Prognostic factors of overall survival of stage III or IV adrenocortical carcinomas (ACC): A multicenter ENS@T study in Journal of Clinical Oncology
2014
AOU San Luigi di Orbassano
Libe R; Borget I; Ronchi CL; Ardito A; Kroiss M; Bertherat J; Quinkler M; Bala M; Beuschlein F; Vezzosi D; Haak H; Leboulleux S; Zaggia B; Fassnacht M; Baudin E;
Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience in Journal of Clinical Oncology
2014
AOU San Luigi di Orbassano
Caffo O; Basso U; Facchini G; Gasparro D; Alesini D; Tucci M; Ortega C; Fratino L; Campadelli E; Lo Re G; Sabbatini R; Procopio G; Zucali PA; D'Angelo A; Donini M; Massari F; Ratta R; Sava T; Messina C; De Giorgi U;
A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC) in Journal of Clinical Oncology
2014
AOU San Luigi di Orbassano
Besse B; Garassino MC; Rajan A; Novello S; Mazieres J; Weiss GJ; Ciomei M; Martignoni M; Petroccione A; Davite C; Giaccone G;
Next-generation sequencing in malignant pleural mesothelioma: A retrospective study in Journal of Clinical Oncology
2014
AOU San Luigi di Orbassano
Scagliotti GV; Iacono ML; Novello S; Libener R; Vatrano S; Righi L; Papotti M; Bironzo P; Monica V; Grosso F;
Final overall survival (OS) results from a phase II study of pemetrexed (Pem) and cisplatin (Cis) with concurrent thoracic radiation (RT) after Pem-Cis induction in patients with unresectable locally advanced (LA) nonsquamous non-small cell lung cancer (NS-NSCLC) in Journal of Clinical Oncology
2014
AOU San Luigi di Orbassano
Novello S; Engel-Riedel W; Serke M; Giraud P; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Garrido P;
Histologic and genotypic re-evaluation of non-small cell lung cancer (NSCLC): A monocentric study in Journal of Clinical Oncology
2014
AOU San Luigi di Orbassano
Vavalá T; Busso M; Righi L; Vatrano S; Cappia S; Sardo D; Rapetti SG; Veltri A; Papotti M; Scagliotti GV; Novello S;
ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM) in Journal of Clinical Oncology
2014
AOU San Luigi di Orbassano
Larson RA; Kim D-W; Jootar S; Pasquini R; Clark RE; Lobo C; Goldberg SL; Shibayama H; Hochhaus A; Saglio G; Kantarjian HM; Kemp C; Deng W; Menssen HD; Hughes TP;
Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath in Journal of Clinical Oncology
2014
AOU San Luigi di Orbassano
Mahon F-X; Baccarani M; Mauro MJ; Hughes TP; Saglio G; Savona M; Szczudlo TK; Menssen HD; Keir CH; Walasek C; Hochhaus A;
Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update in Journal of Clinical Oncology
2013
AOU San Luigi di Orbassano
Larson RA; Hochhaus A; Saglio G; Kim D-W; Jootar S; Le Coutre PD; Reiffers J; Pasquini R; Goldberg SL; Clark RE; Kemp CN; Fan X; Menssen HD; Hughes TP; Kantarjian HM;
Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd in Journal of Clinical Oncology
2013
AOU San Luigi di Orbassano
Saglio G; Hughes TP; Larson RA; Issaragrilsil S; Turkina AG; Steegmann JL; Lopez JL; Nakaseko C; Kalaycio ME; Huguet F; Kemp CN; Fan X; Menssen HD; Kantarjian HM; Hochhaus A;
Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC). in Journal of Clinical Oncology
2013
AOU San Luigi di Orbassano
Gauler TC; Besse B; Novello S; Smit EF; Plummer ER; Delord J-P; Nicodemo M; Santoro A; Barone C; Marchetti P; Conte PF; De Jonge MJ; Awada A; Mariani M; Jannuzzo MG; Petroccione A; Ceruti R; Davite C; Eberhardt WEE;
Natural history of malignant bone disease in renal cancer: Final results of an Italian bone metastases survey in Journal of Clinical Oncology
2012
AOU San Luigi di Orbassano
Santini D; Procopio G; Porta C; Mazzara C; Barni S; Fontana A; Berruti A; Berardi R; Vincenzi B; Ortega C; Ibrahim T; Ottaviani D; Carteni G; Lanzetta G; Virzì V; Silvestris N; Tanca FM; Adamo V; Tonini G; Bracarda S;
Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u) in Journal of Clinical Oncology
2012
AOU San Luigi di Orbassano
Kantarjian H; Flinn IW; Goldberg S; Bunworasate U; Zanichelli MA; Nakamae H; Hughes TP; Hochhaus A; Saglio G; Woodman RC; Blakesley RE; Kemp CN; Kalaycio ME; Larson RA;
NGR-hTNF and doxorubicin in relapsed small-cell lung cancer (SCLC) in Journal of Clinical Oncology
2012
AOU San Luigi di Orbassano
Cavina R; Gregorc V; Novello S; Grossi F; Santoro A; Viganò MG; Levra MG; Lambiase A; Bordignon C;
Updated safety result of a large Italian early access program (EAP) with cabazitaxel plus prednisone (CbzP) in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed during or after docetaxel (D) therapy in Journal of Clinical Oncology
2012
AOU San Luigi di Orbassano
Bracarda S; Di Lorenzo G; Gasparro D; Marchetti P; Boccardo F; Martoni A; Carteni G; Fornarini G; Baldazzi V; Dogliotti L; Messina C; Sisani M;
Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC) in Journal of Clinical Oncology
2012
AOU San Luigi di Orbassano
Bracarda S; Di Lorenzo G; Gasparro D; Marchetti P; Boccardo F; Martoni A; Carteni G; Fornarini G; Baldazzi V; Dogliotti L; Messina C; Sisani M;
Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC) in Journal of Clinical Oncology
2011
AOU San Luigi di Orbassano
Vigano' MG; Cavina R; Novello S; Grossi F; Santoro A; Gregorc V; Scagliotti G; Garassino IM; Rossoni G; Levra MG; Genova C; Caligaris-Cappio F; Lambiase A; Bordignon C;